MCID: ACQ022
MIFTS: 47

Acquired Generalized Lipodystrophy

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Muscle diseases, Rare diseases, Skin diseases

Aliases & Classifications for Acquired Generalized Lipodystrophy

MalaCards integrated aliases for Acquired Generalized Lipodystrophy:

Name: Acquired Generalized Lipodystrophy 12 52 58 36 54 15
Lawrence Syndrome 12 52 58
Acquired Lipoatrophic Diabetes 52 58
Lawrence-Seip Syndrome 52 58
Familial Generalized Lipodystrophy 71

Characteristics:

Orphanet epidemiological data:

58
acquired generalized lipodystrophy
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

Classifications:

Orphanet: 58  
Rare skin diseases
Rare endocrine diseases


Summaries for Acquired Generalized Lipodystrophy

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 79086 Definition A rare lipodystrophic syndrome characterized by loss of adipose tissue , and is a syndrome of insulin resistance that leads to increased cardiovascular risk. Acquired generalized lipodystrophy is related to a selective loss of subcutaneous adipose tissue occurring exclusively at the extremities (face, legs, arms, palms and sometimes soles). Epidemiology More than 100 cases have been described and the female to male ratio is 3:1. Clinical description The clinical phenotype is similar to that of Berardinelli-Seip syndrome (see this term), but lipoatrophy appears secondarily during childhood, adolescence or adulthood, and as a result the syndrome is thought to be acquired. In some cases, loss of adipose tissue is localized, especially if it is preceded by a panniculitis. The syndrome is associated with a voracious appetite and an acceleration of growth in adolescents. One third of cases are accompanied by acanthosis nigricans and a polycystic ovary syndrome (see these terms). Hepatomegaly with steatosis and a risk of cirrhogenous progression is common. Biologically, hyperinsulinemia and insulin-resistant diabetes are observed, often associated with severe hypertriglyceridemia with low plasma levels of leptin and adiponectin. Proteinuria associated with focal segmental glomerulosclerosis or with membranoproliferative glomerulonephritis have been reported recently, as well as dysregulation of growth hormone . Three types of the disease have been described: 1) a form with panniculitis (inflammatory nodules followed by lipoatrophy), 2) an autoimmune form that is readily associated with other syndromes such as chronic active hepatitis, Hashimoto struma and hemolytic anemia , but also with dermatomyositis and Sjogren's syndrome (see these terms), 3) idiopathic. Etiology The cause of the disease remains unknown. There may be infectious triggering factors (there was a recent case of the panniculitis type that appeared after tuberculosis) or an autoimmune mechanism. A recent publication showed activation of the classical complement pathway (low C4). This is in contrast to acquired partial lipodystrophy (see this term) which affects the upper half of the body and is characterized by an activation of the alternative complement pathway (low C3). Progression towards partial lipoatrophy, focal or generalized, has been reported in patients with dermatomyositis, amongst whom this could be a late relapse, and it is more common that the antibody anti-p155 is present. The hypothesis of an underlying genetic factor has not been rejected. Diagnostic methods Diagnosis is clinical and should be confirmed by an assessment of body fat, in particular by biphotonic absorptiometry and magnetic resonance imaging . Differential diagnosis Differential diagnoses include other forms of extreme insulin resistance (Rabson-Mendenhall syndrome, leprechaunism, Berardinelli type lipodystrophy and insulin resistance syndromes types A and B; see these terms) and other lipodystrophies. Management and treatment The treatment of the metabolic manifestations is a priori no different to the treatment of other forms of insulin resistance: physical exercise, insulin sensitizers such as metformin or pioglitazone, insulin (or preferably insulin analogues), antihypertensives, and monitoring and treatment of hypertriglyceridemia. The efficacy of recombinant human leptin has been demonstrated on the metabolic level but this therapy is not available in all countries. In serious autoimmune forms of the disease, immunosuppressive therapy may be indicated. Prognosis The prognosis is not well known but is probably related to cardiovascular risk (linked to the insulin-resistance syndrome) and to the underlying cause of the disease. Visit the Orphanet disease page for more resources.

MalaCards based summary : Acquired Generalized Lipodystrophy, also known as lawrence syndrome, is related to fatty liver disease, nonalcoholic 1 and hyperinsulinism. An important gene associated with Acquired Generalized Lipodystrophy is ADIPOQ (Adiponectin, C1Q And Collagen Domain Containing), and among its related pathways/superpathways are Glucose / Energy Metabolism and Adipogenesis. The drugs Immunoglobulins and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and ovary, and related phenotypes are generalized lipodystrophy and hyperinsulinemia

Disease Ontology : 12 A complete generalized lipodystrophy that is charcterized by generalized disappearance of fat occurring during childhood and adolescence where normal body fat is present at birth.

KEGG : 36 Acquired generalized lipodystrophy (AGL), also called the Lawrence syndrome, is one subtype of acquired lipodystrophy caused by autoimmune disease, panniculitis or idiopathic. The disorder appears during the childhood and adolescence. Clinically, loss of subcutaneous fat occurs highly variable, exclusively at the face and extremities including legs, palms and some soles. In rare cases, intraabdomianl fat and bone marrow fat may also be spared. Similarly to congential generalized lipodystrophy, people with the disorder usually appear severe hepatic steatosis and fibrosis, diabetes, and hypertriglyceridemia. Metreleptin, as a recombinant analog of human leptin, has been approved for the treatment for the disorder as well as diet.

Wikipedia : 74 Acquired generalized lipodystrophy (also known as "Lawrence syndrome," and "Lawrence-Seip syndrome",... more...

Related Diseases for Acquired Generalized Lipodystrophy

Diseases in the Acquired Generalized Lipodystrophy family:

Lipodystrophy, Congenital Generalized, Type 2 Lipodystrophy, Congenital Generalized, Type 1
Lipodystrophy, Congenital Generalized, Type 3 Lipodystrophy, Congenital Generalized, Type 4
Congenital Generalized Lipodystrophy

Diseases related to Acquired Generalized Lipodystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease, nonalcoholic 1 30.4 RETN LEP ADIPOQ
2 hyperinsulinism 30.2 RETN LEP ADIPOQ
3 acanthosis nigricans 30.2 LMNA LEP ADIPOQ
4 hyperglycemia 30.1 RETN LEP ADIPOQ
5 fatty liver disease 30.0 RETN LEP ADIPOQ
6 umbilical hernia 29.9 BSCL2 AGPAT2
7 osteoporosis 29.7 RETN LMNA LEP ADIPOQ
8 lipid metabolism disorder 29.7 RETN LMNA LEP ADIPOQ
9 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 29.5 ZMPSTE24 LMNA LEP BSCL2 AGPAT2 ADIPOQ
10 berardinelli-seip congenital lipodystrophy 29.2 LEP CAVIN1 BSCL2 AGPAT2
11 diabetes mellitus 29.2 RETN LMNA LEP BSCL2 ADIPOQ
12 lipodystrophy, congenital generalized, type 1 28.4 ZMPSTE24 LMNA LEP BSCL2 AGPAT2 ADIPOQ
13 congenital generalized lipodystrophy 27.5 ZMPSTE24 LMNA LEP CIDEC CAVIN1 BSCL2
14 hypertriglyceridemia, familial 10.4
15 hypothalamic obesity 10.3 RETN LEP
16 nontuberculous mycobacterial lung disease 10.3 LEP ADIPOQ
17 bone mineral density quantitative trait locus 8 10.3
18 bone mineral density quantitative trait locus 15 10.3
19 muscle hypertrophy 10.3
20 panniculitis 10.2
21 autoimmune disease 10.1
22 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.1
23 adult syndrome 10.1 LEP ADIPOQ
24 rare genetic diabetes mellitus 10.1 LMNA BSCL2
25 donohue syndrome 10.1 BSCL2 AGPAT2
26 spastic paraplegia 17, autosomal dominant 10.1 BSCL2 AGPAT2
27 idiopathic recurrent pericarditis 10.1 RETN LEP ADIPOQ
28 pericarditis 10.1 RETN LEP ADIPOQ
29 obesity-hypoventilation syndrome 10.1 RETN LEP ADIPOQ
30 abdominal obesity-metabolic syndrome quantitative trait locus 2 10.1 RETN LEP ADIPOQ
31 maturity-onset diabetes of the young, type 1 10.1 RETN LEP ADIPOQ
32 apnea, obstructive sleep 10.1 RETN LEP ADIPOQ
33 abdominal obesity-metabolic syndrome 1 10.1 RETN LEP ADIPOQ
34 nutritional deficiency disease 10.1 RETN LEP ADIPOQ
35 sleep apnea 10.1 RETN LEP ADIPOQ
36 peripheral t-cell lymphoma 10.1
37 non-alcoholic steatohepatitis 10.1
38 autoimmune hepatitis 10.1
39 hemolytic anemia 10.1
40 acquired lipodystrophy 10.1
41 mandibuloacral dysplasia with type a lipodystrophy 10.1 ZMPSTE24 LMNA
42 gestational diabetes 10.0 RETN LEP ADIPOQ
43 acroosteolysis 10.0 ZMPSTE24 LMNA
44 prediabetes syndrome 10.0 LEP ADIPOQ
45 leptin deficiency or dysfunction 10.0 RETN LEP ADIPOQ
46 hypertrichosis 10.0
47 laminopathy 10.0 ZMPSTE24 LMNA
48 anorexia nervosa 10.0 RETN LEP ADIPOQ
49 reynolds syndrome 10.0 ZMPSTE24 LMNA
50 overnutrition 10.0 RETN LEP ADIPOQ

Graphical network of the top 20 diseases related to Acquired Generalized Lipodystrophy:



Diseases related to Acquired Generalized Lipodystrophy

Symptoms & Phenotypes for Acquired Generalized Lipodystrophy

Human phenotypes related to Acquired Generalized Lipodystrophy:

58 31 (show all 28)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 generalized lipodystrophy 58 31 obligate (100%) Obligate (100%) HP:0009064
2 hyperinsulinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000842
3 autoimmunity 58 31 frequent (33%) Frequent (79-30%) HP:0002960
4 hepatic steatosis 58 31 frequent (33%) Frequent (79-30%) HP:0001397
5 cardiomyopathy 58 31 frequent (33%) Frequent (79-30%) HP:0001638
6 progeroid facial appearance 58 31 frequent (33%) Frequent (79-30%) HP:0005328
7 insulin-resistant diabetes mellitus 58 31 frequent (33%) Frequent (79-30%) HP:0000831
8 calf muscle pseudohypertrophy 58 31 frequent (33%) Frequent (79-30%) HP:0003707
9 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
10 proteinuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0000093
11 myopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0003198
12 hypertriglyceridemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002155
13 cirrhosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001394
14 hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0000822
15 polycystic ovaries 58 31 occasional (7.5%) Occasional (29-5%) HP:0000147
16 generalized hirsutism 58 31 occasional (7.5%) Occasional (29-5%) HP:0002230
17 generalized hyperpigmentation 58 31 occasional (7.5%) Occasional (29-5%) HP:0007440
18 acanthosis nigricans 58 31 occasional (7.5%) Occasional (29-5%) HP:0000956
19 accelerated skeletal maturation 58 31 occasional (7.5%) Occasional (29-5%) HP:0005616
20 panniculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0012490
21 abnormality of complement system 58 31 occasional (7.5%) Occasional (29-5%) HP:0005339
22 acute pancreatitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001735
23 lymphoma 58 31 very rare (1%) Very rare (<4-1%) HP:0002665
24 astrocytoma 58 31 very rare (1%) Very rare (<4-1%) HP:0009592
25 unicameral bone cyst 58 31 very rare (1%) Very rare (<4-1%) HP:0012064
26 abnormality of lipid metabolism 58 Frequent (79-30%)
27 abnormality of cardiovascular system physiology 58 Frequent (79-30%)
28 insulin resistance 58 Very frequent (99-80%)

MGI Mouse Phenotypes related to Acquired Generalized Lipodystrophy:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.2 ADIPOQ AGL AGPAT2 BSCL2 CAVIN1 CIDEC
2 homeostasis/metabolism MP:0005376 10.18 ADIPOQ AGL AGPAT2 BSCL2 CAVIN1 CIDEC
3 adipose tissue MP:0005375 10.16 ADIPOQ AGPAT2 BSCL2 CIDEC LEP LMNA
4 growth/size/body region MP:0005378 10.11 ADIPOQ AGPAT2 BSCL2 CAVIN1 CIDEC LEP
5 hematopoietic system MP:0005397 10.04 ADIPOQ AGPAT2 BSCL2 CIDEC LEP LMNA
6 liver/biliary system MP:0005370 10.02 ADIPOQ AGL AGPAT2 BSCL2 CIDEC LEP
7 endocrine/exocrine gland MP:0005379 10 ADIPOQ AGPAT2 BSCL2 LEP LMNA ZMPSTE24
8 immune system MP:0005387 10 ADIPOQ AGPAT2 BSCL2 LEP LMNA RETN
9 integument MP:0010771 9.98 ADIPOQ AGPAT2 BSCL2 CIDEC LEP LMNA
10 digestive/alimentary MP:0005381 9.93 AGPAT2 BSCL2 LEP LMNA ZMPSTE24
11 mortality/aging MP:0010768 9.92 ADIPOQ AGL AGPAT2 BSCL2 CAVIN1 LEP
12 limbs/digits/tail MP:0005371 9.88 AGL AGPAT2 BSCL2 LEP LMNA ZMPSTE24
13 muscle MP:0005369 9.73 ADIPOQ AGL CAVIN1 LEP LMNA ZMPSTE24
14 renal/urinary system MP:0005367 9.7 ADIPOQ AGPAT2 BSCL2 CAVIN1 LEP LMNA
15 respiratory system MP:0005388 9.35 ADIPOQ AGL CAVIN1 LEP LMNA
16 skeleton MP:0005390 9.17 ADIPOQ AGL AGPAT2 BSCL2 LEP LMNA

Drugs & Therapeutics for Acquired Generalized Lipodystrophy

Drugs for Acquired Generalized Lipodystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunoglobulins Phase 4
2 Antibodies Phase 4

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy Recruiting NCT04026178 Phase 4 Metreleptin
2 Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy Recruiting NCT02262806 Phase 3 Metreleptin
3 Expanded-Access for the Use of Metreleptin in Patients With Partial Lipodystrophy Associated With Diabetes Mellitus or Hypertriglyceridemia Active, not recruiting NCT02404896 Phase 2 Metreleptin

Search NIH Clinical Center for Acquired Generalized Lipodystrophy

Genetic Tests for Acquired Generalized Lipodystrophy

Anatomical Context for Acquired Generalized Lipodystrophy

MalaCards organs/tissues related to Acquired Generalized Lipodystrophy:

40
Bone, Skin, Ovary, Bone Marrow, Liver, T Cells, Adipocyte

Publications for Acquired Generalized Lipodystrophy

Articles related to Acquired Generalized Lipodystrophy:

(show top 50) (show all 67)
# Title Authors PMID Year
1
Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. 54 61
18076675 2008
2
Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations. 54 61
15256772 2004
3
Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. 54 61
12502655 2003
4
Serum adiponectin and leptin levels in patients with lipodystrophies. 54 61
11994394 2002
5
Imaging spectrum of abnormal subcutaneous and visceral fat distribution. 61
32056035 2020
6
Acquired generalized lipodystrophy under immune checkpoint inhibition. 61
31077337 2020
7
Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy. 61
32010873 2020
8
A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA. 61
32524008 2020
9
Leptin induces TNF╬▒-dependent inflammation in acquired generalized lipodystrophy and combined Crohn's disease. 61
31822667 2019
10
Surgical fat removal exacerbates metabolic disorders but not atherogenesis in LDLR-/- mice fed on high-fat diet. 61
31780791 2019
11
Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes. 61
31434650 2019
12
Acquired Lipodystrophy Associated With Nivolumab in a Patient With Advanced Renal Cell Carcinoma. 61
30779841 2019
13
Fatty Liver and Autoimmune Hepatitis: Two Forms of Liver Involvement in Lipodystrophies. 61
31559327 2019
14
An overview of lipodystrophy and the role of the complement system. 61
31177059 2019
15
Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin. 61
30923630 2019
16
Diagnosis and treatment of lipodystrophy: a step-by-step approach. 61
29704234 2019
17
Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency. 61
29846625 2018
18
Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. 61
29644599 2018
19
Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy. 61
30283460 2018
20
Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis. 61
29610677 2018
21
Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy. 61
29044029 2017
22
Acquired Generalized Lipodystrophy Following Immune Thrombocytopenia. 61
28549922 2017
23
Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review. 61
27967300 2017
24
Lipodystrophy Syndromes. 61
27823605 2016
25
Bone imaging findings in genetic and acquired lipodystrophic syndromes: an imaging study of 24 cases. 61
27631079 2016
26
Cover Image: Acquired generalized lipodystrophy in a patient with systemic lupus erythematosus. 61
27484277 2016
27
Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. 61
26465174 2016
28
Lymphoma in acquired generalized lipodystrophy. 61
25864863 2016
29
Acquired generalized lipodystrophy in a young lean Chinese girl. Case Report. 61
26859586 2015
30
A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin. 61
26390101 2015
31
A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma. 61
26252356 2015
32
Acquired generalized lipodystrophy associated with peripheral T cell lymphoma with cutaneous infiltration. 61
24168394 2015
33
Leptin in congenital and HIV-associated lipodystrophy. 61
25267014 2015
34
Exploring the pathophysiology behind the more common genetic and acquired lipodystrophies. 61
24152769 2014
35
Post-liver transplant leptin results in resolution of severe recurrence of lipodystrophy-associated nonalcoholic steatohepatitis. 61
24007548 2013
36
Response to comments on "Late-onset acquired generalized lipodystrophy with muscle involvement". 61
23962584 2013
37
Comment on: late-onset acquired generalized lipodystrophy with muscle involvement. 61
23985087 2013
38
The liver diseases of lipodystrophy: the long-term effect of leptin treatment. 61
23439261 2013
39
Late-onset acquired generalized lipodystrophy with muscle involvement. 61
22188950 2012
40
Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. 61
22965160 2012
41
Cardiomyopathy in congenital and acquired generalized lipodystrophy: a clinical assessment. 61
20616664 2010
42
Case report: unicameral bone cysts in a young patient with acquired generalized lipodystrophy. 61
19924491 2010
43
Acquired generalized lipodystrophy associated with autoimmune hepatitis and low serum C4 level. 61
21274335 2010
44
Complement abnormalities in acquired lipodystrophy revisited. 61
18854390 2009
45
Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. 61
17940115 2008
46
[Acquired generalized lipodystrophy. Literature review and own observation]. 61
19145855 2008
47
Acquired generalized lipodystrophy (panniculitis variety) triggered by pulmonary tuberculosis. 61
17651183 2007
48
[Primary lipodystrophies]. 61
17320032 2007
49
Dysregulation of growth hormone in acquired generalized lipodystrophy. 61
15573230 2004
50
A case of acquired generalized lipodystrophy with cerebellar degeneration and type 2 diabetes mellitus. 61
17491704 2004

Variations for Acquired Generalized Lipodystrophy

Expression for Acquired Generalized Lipodystrophy

Search GEO for disease gene expression data for Acquired Generalized Lipodystrophy.

Pathways for Acquired Generalized Lipodystrophy

Pathways related to Acquired Generalized Lipodystrophy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.92 BSCL2 AGPAT2 ADIPOQ
2 11.29 ZMPSTE24 RETN LMNA LEP BSCL2 AGPAT2
3 10.55 LEP ADIPOQ
4 10.3 LEP ADIPOQ

GO Terms for Acquired Generalized Lipodystrophy

Cellular components related to Acquired Generalized Lipodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.1 ZMPSTE24 CIDEC CAVIN1 BSCL2 AGPAT2 ADIPOQ

Biological processes related to Acquired Generalized Lipodystrophy according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 fatty acid beta-oxidation GO:0006635 9.49 LEP ADIPOQ
2 response to activity GO:0014823 9.48 LEP ADIPOQ
3 positive regulation of cytokine production GO:0001819 9.46 LEP AGPAT2
4 nucleus organization GO:0006997 9.43 ZMPSTE24 LMNA
5 regulation of glucose metabolic process GO:0010906 9.4 ZMPSTE24 ADIPOQ
6 lipid droplet organization GO:0034389 9.37 CIDEC BSCL2
7 positive regulation of cold-induced thermogenesis GO:0120162 9.33 LEP BSCL2 ADIPOQ
8 nuclear envelope organization GO:0006998 9.32 ZMPSTE24 LMNA
9 determination of adult lifespan GO:0008340 9.26 ZMPSTE24 LEP
10 regulation of protein localization to nucleus GO:1900180 8.96 LMNA LEP
11 response to nutrient GO:0007584 8.8 LEP AGL ADIPOQ

Molecular functions related to Acquired Generalized Lipodystrophy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 RETN LEP ADIPOQ

Sources for Acquired Generalized Lipodystrophy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....